Dysfunction of complement receptors CR3 (CD11b/18) and CR4 (CD11c/18) in pre-eclampsia: a genetic and functional study

被引:11
|
作者
Lokki, A., I [1 ,2 ]
Teirila, L. [1 ,3 ]
Triebwasser, M. [4 ]
Daly, E. [5 ]
Bhattacharjee, A. [6 ,7 ]
Uotila, L. [8 ]
Llort Asens, M. [9 ]
Kurki, M., I [10 ,11 ]
Perola, M. [12 ]
Auro, K. [13 ]
Salmon, J. E. [14 ]
Daly, M. [15 ,16 ]
Atkinson, J. P. [4 ]
Laivuori, H. [2 ,16 ,17 ,18 ]
Fagerholm, S. [9 ]
Meri, S. [1 ,3 ]
Finnpec [17 ,18 ]
机构
[1] Univ Helsinki, Translat Immunol Res Program, Res Programs Unit, Helsinki, Finland
[2] Tampere Univ, Tampere Univ Hosp, Fac Med & Hlth Technol, Dept Obstet & Gynecol, Tampere, Finland
[3] Univ Helsinki, Helsinki Univ Hosp, Bacteriol & Immunol, Helsinki, Finland
[4] Washington Univ, Dept Med, Div Rheumatol, Sch Med, St Louis, MO USA
[5] Hosp & Harvard Med Sch, Boston, MA USA
[6] Herantis Pharma Plc, Espoo, Finland
[7] Univ Helsinki, Neurosci Ctr, HiLife, Helsinki, Finland
[8] Univ Helsinki, Res Serv, Helsinki, Finland
[9] Univ Helsinki, Fac Bio & Environm Sci, Mol & Integrat Biosci Res Program, Helsinki, Finland
[10] Kuopio Univ Hosp, Neurosurg Neuro Ctr, Helsinki, Finland
[11] Broad Inst MIT & Harvard, Stanley Ctr Psychiat Res, Cambridge, MA USA
[12] Natl Inst Hlth & Welf, Dept Hlth, Helsinki, Finland
[13] Natl Inst Hlth & Welf, Dept Govt Serv, Helsinki, Finland
[14] Hosp Special Surg, Dept Med, Weill Cornell Med, New York, NY USA
[15] Massachusetts Gen Hosp, Analyt & Translat Genet Unit, Boston, MA USA
[16] Univ Helsinki, Helsinki Inst Life Sci, Inst Mol Med Finland, Helsinki, Finland
[17] Univ Helsinki, Med & Clin Genet, Helsinki, Finland
[18] Helsinki Univ Hosp, Helsinki, Finland
基金
芬兰科学院; 美国国家卫生研究院;
关键词
β 2‐ integrins; complement receptors; complement system; genetic association; pre‐ eclampsia; pregnancy; LEUKOCYTE ADHESION GLYCOPROTEIN; MATERNAL SUSCEPTIBILITY LOCUS; GENOME-WIDE SCAN; APOPTOTIC CELLS; I-DOMAIN; RECOGNITION SITE; ALPHA-SUBUNIT; INTEGRIN; MAC-1; PHAGOCYTOSIS;
D O I
10.1111/1471-0528.16660
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective To study genetic variants and their function within genes coding for complement receptors in pre-eclampsia. Design A case-control study. Setting Pre-eclampsia is a common vascular disease of pregnancy. The clearance of placenta-derived material is one of the functions of the complement system in pregnancy. Population We genotyped 500 women with pre-eclamptic pregnancies and 190 pregnant women without pre-eclampsia, as controls, from the FINNPEC cohort, and 122 women with pre-eclamptic pregnancies and 1905 controls from the national FINRISK cohort. Methods The functional consequences of genotypes discovered by targeted exomic sequencing were explored by analysing the binding of the main ligand iC3b to mutated CR3 or CR4, which were transiently expressed on the surface of COS-1 cells. Main outcome measures Allele frequencies were compared between pre-eclamptic pregnancies and controls in genetic studies. The functional consequences of selected variants were measured by binding assays. Results The most significantly pre-eclampsia-linked CR3 variant M441K (P = 4.27E-4, OR = 1.401, 95% CI = 1.167-1.682) displayed a trend of increased adhesion to iC3b (P = 0.051). The CR4 variant A251T was found to enhance the adhesion of CR4 to iC3b, whereas W48R resulted in a decrease of the binding of CR4 to iC3b. Conclusions Results suggest that changes in complement-facilitated phagocytosis are associated with pre-eclampsia. Further studies are needed to ascertain whether aberrant CR3 and CR4 activity leads to altered pro- and anti-inflammatory cytokine responses in individuals carrying the associated variants, and the role of these receptors in pre-eclampsia pathogenesis. Tweetable abstract Genetic variants of complement receptors CR3 and CR4 have functional consequences that are associated with pre-eclampsia.
引用
收藏
页码:1282 / 1291
页数:10
相关论文
共 50 条
  • [31] Total cell content of CR3 (CD11b/CD18) and LFA-1 (CD11a/CD18) in neonatal neutrophils: Relationship to gestational age
    McEvoy, LT
    ZakemCloud, H
    Tosi, MF
    BLOOD, 1996, 87 (09) : 3929 - 3933
  • [32] STAUROSPORINE INHIBITS NEUTROPHIL PHAGOCYTOSIS BUT NOT IC3B BINDING MEDIATED BY CR3 (CD11B/CD18)
    ROUBEY, RAS
    ROSS, GD
    MERRILL, JT
    WALTON, F
    REED, W
    WINCHESTER, RJ
    BUYON, JP
    JOURNAL OF IMMUNOLOGY, 1991, 146 (10): : 3557 - 3562
  • [33] CYTOPLASMIC TAILS OF HUMAN-COMPLEMENT RECEPTOR TYPE-3 (CR3, CD11B CD18) REGULATE LIGAND AVIDITY AND THE INTERNALIZATION OF OCCUPIED RECEPTORS
    RABB, H
    MICHISHITA, M
    SHARMA, CP
    BROWN, D
    ARNAOUT, MA
    JOURNAL OF IMMUNOLOGY, 1993, 151 (02): : 990 - 1002
  • [34] Aberrant integrin (CR4; αxβ2; CD11c/CD18) oscillations on neutrophils in a mild form of pyoderma gangrenosum
    Shaya, S
    Kindzelskii, AL
    Minor, J
    Moore, EC
    Todd, RF
    Petty, HR
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1998, 111 (01) : 154 - 158
  • [35] Differential expression of complement receptors (CD11b, CD11c) in rabbit Peyer's patches and appendix
    Fujimura, Y
    Owen, RL
    Iida, M
    Ohashi, K
    FASEB JOURNAL, 1998, 12 (05): : A884 - A884
  • [36] The complement receptor 3, CR3 (CD11b/CD18), on T lymphocytes:: activation-dependent up-regulation and regulatory function
    Wagner, C
    Hänsch, GM
    Stegmaier, S
    Denefleh, B
    Hug, F
    Schoels, M
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2001, 31 (04) : 1173 - 1180
  • [37] THE FUNCTION OF HUMAN NK CELLS IS ENHANCED BY BETA-GLUCAN, A LIGAND OF CR3 (CD11B/CD18)
    DIRENZO, L
    YEFENOF, E
    KLEIN, E
    EUROPEAN JOURNAL OF IMMUNOLOGY, 1991, 21 (07) : 1755 - 1758
  • [38] Role of the lectin domain of Mac-1/CR3 (CD11b/CD18) in regulating intercellular adhesion
    Gordon D. Ross
    Immunologic Research, 2002, 25 : 219 - 227
  • [39] Role of the lectin domain of Mac-1/CR3 (CD11b/CD18) in regulating intercellular adhesion
    Ross, GD
    IMMUNOLOGIC RESEARCH, 2002, 25 (03) : 219 - 227
  • [40] CRYSTAL-STRUCTURE OF THE A-DOMAIN FROM THE A-SUBUNIT OF INTEGRIN CR3 (CD11B/CD18)
    LEE, JO
    RIEU, P
    ARNAOUT, MA
    LIDDINGTON, R
    CELL, 1995, 80 (04) : 631 - 638